David M. Weber - Mar 31, 2022 Form 4 Insider Report for ABIOMED INC (NASD)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Marc A. Began (by power of attorney)
Stock symbol
NASD
Transactions as of
Mar 31, 2022
Transactions value $
-$2,550,000
Form type
4
Date filed
4/4/2022, 05:07 PM
Previous filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $.01 par value Sale -$2.55M -7.5K -6.06% $340.00* 116K Mar 31, 2022 Direct F1, F2
holding NASD Common Stock, $.01 par value 15.5K Mar 31, 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (right to buy) 10K Mar 31, 2022 Common Stock 0 $66.25 Direct F3, F4
holding NASD Stock Option (right to buy) 7K Mar 31, 2022 Common Stock 0 $99.62 Direct F4, F5
holding NASD Stock Option (right to buy) 8K Mar 31, 2022 Common Stock 0 $134.51 Direct F4, F5
holding NASD Stock Option (right to buy) 6.5K Mar 31, 2022 Common Stock 0 $381.97 Direct F4, F5
holding NASD Stock Option (right to buy) 6K Mar 31, 2022 Common Stock 0 $266.39 Direct F4, F5
holding NASD Stock Option (right to buy) 5K Mar 31, 2022 Common Stock 0 $223.90 Direct F4, F5
holding NASD Stock Option (right to buy) 4.97K Mar 31, 2022 Common Stock 0 $283.88 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of common stock pursuant to reporting owner's 10b5-1 plan.
F2 This price represents the sale price of the transactions on the reported date at $340.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F3 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
F4 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
F5 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.